1. Home
  2. DOYU vs TTRX Comparison

DOYU vs TTRX Comparison

Compare DOYU & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DouYu International Holdings Limited ADS

DOYU

DouYu International Holdings Limited ADS

HOLD

Current Price

$4.59

Market Cap

153.0M

Sector

Technology

ML Signal

HOLD

Logo Turn Therapeutics Inc.

TTRX

Turn Therapeutics Inc.

HOLD

Current Price

$6.93

Market Cap

174.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DOYU
TTRX
Founded
2014
2015
Country
China
United States
Employees
N/A
2
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
153.0M
174.9M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
DOYU
TTRX
Price
$4.59
$6.93
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
$7.00
$8.00
AVG Volume (30 Days)
31.2K
55.8K
Earning Date
05-19-2026
05-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.28
$2.57
52 Week High
$9.34
$6.98

Technical Indicators

Market Signals
Indicator
DOYU
TTRX
Relative Strength Index (RSI) 39.95 69.17
Support Level $4.41 $3.92
Resistance Level $4.98 N/A
Average True Range (ATR) 0.18 0.60
MACD -0.04 0.03
Stochastic Oscillator 13.08 93.96

Price Performance

Historical Comparison
DOYU
TTRX

About DOYU DouYu International Holdings Limited ADS

DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company operates its platform on both PC and mobile apps, through which users can enjoy immersive and interactive games and entertainment live streaming. It generates revenues through live streaming and advertisement.

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Share on Social Networks: